Drug delivery options and therapeutic advances in the management of erectile dysfunction.


Journal

Expert opinion on drug delivery
ISSN: 1744-7593
Titre abrégé: Expert Opin Drug Deliv
Pays: England
ID NLM: 101228421

Informations de publication

Date de publication:
09 2020
Historique:
pubmed: 13 6 2020
medline: 2 2 2021
entrez: 13 6 2020
Statut: ppublish

Résumé

Erectile dysfunction (ED) is defined as the inability to achieve or maintain an erection sufficient for satisfactory sexual performance. It is estimated that 20-30% of adult men will have at least one episode of ED during their lifetime and the prevalence increases with age. ED is known to have significant negative psychological implications for men, resulting in impaired functional status and a greater prevalence of anxiety and depression. Medications for the treatment of erectile dysfunction largely revolve around oral, injection, and topical therapies. Though all three modalities are widely used, each delivery option has its own advantages and specific indications. Likewise, there are several new developing treatments for ED that may change the landscape of treatment. The goal of this review is to summarize contemporary drug delivery options used in the treatment of ED and highlight future promising pharmacological developments. There are a myriad of new developments on the horizon including new PDE5Is and drug targets, nanotechnology enhancements, stem cell and gene therapy, shockwave therapy, and platelet-rich plasma injections. These are all promising new methods to not only treat ED but also to address the pathology and prevent or eliminate further damage.

Identifiants

pubmed: 32531183
doi: 10.1080/17425247.2020.1782383
doi:

Substances chimiques

Pharmaceutical Preparations 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1259-1268

Auteurs

P T Grice (PT)

Nottingham Urology Centre, Nottingham University Hospitals NHS Trust , Nottingham, UK.

J Liu (J)

James Buchanan Brady Urological Institute, Johns Hopkins Hospital , Baltimore, Maryland, United States.

A T Gabrielson (AT)

James Buchanan Brady Urological Institute, Johns Hopkins Hospital , Baltimore, Maryland, United States.

I Pearce (I)

Manchester Andrology Centre, Manchester Royal Infirmary, Manchester University Hospitals NHS Foundation Trust , UK.

T J Bivalacqua (TJ)

James Buchanan Brady Urological Institute, Johns Hopkins Hospital , Baltimore, Maryland, United States.

V Modgil (V)

Manchester Andrology Centre, Manchester Royal Infirmary, Manchester University Hospitals NHS Foundation Trust , UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH